Related Experiment Video
Updated: May 28, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
MTAP Deficiency as a Metabolic Vulnerability in Cancer: Implications for Synthetic Lethal Therapy
Hiroaki Ikushima1, Hidenori Kage1
1Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
None:
The homozygous deletion of the chromosome 9p21.3 locus, which includes cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) and methylthioadenosine phosphorylase (MTAP) genes, is one of the most common genomic alterations in cancer. MTAP encodes an essential enzyme in the methionine salvage pathway. Historically, deletions at this locus have been characterized primarily by cell cycle dysregulation driven by CDKN2A/B loss. However, recent studies have revealed that the co-deletion of MTAP exposes profound metabolic vulnerabilities. Loss of the MTAP function increases cellular dependency on protein arginine methyltransferase 5 (PRMT5). Consequently, targeted PRMT5 inhibition effectively induces synthetic lethality specifically in MTAP-deleted tumors. Based on this unique mechanism, the development of novel therapeutic agents exploiting this synthetic lethality is actively underway. In this review, we provide a comprehensive overview of the physiological roles of the MTAP-PRMT5 axis and the mechanistic principles underlying this synthetic lethality in MTAP-deficient cells. Furthermore, drawing upon insights from the analysis of real-world patient data, we discuss the clinical and molecular characteristics of MTAP-deleted tumors, review the landscape of ongoing clinical trials, and explore novel therapeutic strategies.
More Related Videos
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...

